LifeTech Scientific Corporation (HK:1302)
:1302
Want to see HK:1302 full AI Analyst Report?
1302 Stock Chart & Stats
HK$1.58
HK$0.01(0.75%)
At close: 4:00 PM EST
HK$1.58
HK$0.01(0.75%)
Day’s Range― - ―
52-Week RangeHK$1.41 - HK$2.44
Previous CloseN/A
Volume6.38M
Average Volume (3M)26.58M
Market Cap
HK$8.51B
Enterprise ValueHK$7.22B
Total Cash (Recent Filing)HK$1.20B
Total Debt (Recent Filing)HK$8.04M
Price to Earnings (P/E)42.5
Beta0.92
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding4,631,712,400
10 Day Avg. Volume33,345,600
30 Day Avg. Volume26,582,987
Financial Highlights & Ratios
PEG Ratio-1.21
Price to Book (P/B)1.74
Price to Sales (P/S)4.59
P/FCF Ratio12.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.08
Revenue Forecast (FY)HK$1.53B
Bulls Say, Bears Say
Bulls Say
Revenue Re-accelerationA durable recovery in top-line (+50.9% YoY in 2025) signals renewed product adoption and market traction for its interventional device portfolio. Sustained revenue growth supports economies of scale, funding for R&D and commercialization, and long-term market share expansion if maintained.
Conservative Capital StructureExtremely low leverage provides durable financial flexibility: lower refinancing and solvency risk, capacity to fund organic growth or targeted M&A, and resilience against reimbursement or procedure-volume shocks, supporting long-term strategic options without heavy interest burden.
Improved Free Cash Flow ConversionStrong FCF in 2025 with ~0.90x conversion of net income indicates the business can generate cash from operations to fund capex, commercialization, and working capital. Durable cash generation reduces dependence on external financing and supports reinvestment in growth.
Bears Say
Material Margin CompressionSteep, persistent margin deterioration erodes the company's ability to convert revenue into profits. If driven by structural cost increases, pricing pressure, or adverse product mix, compressed margins can limit reinvestment, depress sustainable earnings power, and weaken long-term profitability.
Declining Return On EquityFalling ROE signals weaker capital efficiency and lower returns for shareholders. Persistent ROE decline suggests the company may be struggling to monetize its expanded equity base or investments, which can constrain long-term value creation unless operating performance meaningfully improves.
Volatile Cash ConversionInconsistent cash conversion and swings in FCF reduce predictability of funding for R&D, inventory and expansion. Persistent variability heightens refinancing and working-capital risk, complicating multi‑period planning and making sustainable investment pacing harder for management.
LifeTech Scientific Corporation News
1302 FAQ
What was LifeTech Scientific Corporation’s price range in the past 12 months?
LifeTech Scientific Corporation lowest stock price was HK$1.41 and its highest was HK$2.44 in the past 12 months.
What is LifeTech Scientific Corporation’s market cap?
LifeTech Scientific Corporation’s market cap is HK$8.51B.
When is LifeTech Scientific Corporation’s upcoming earnings report date?
LifeTech Scientific Corporation’s upcoming earnings report date is Aug 28, 2026 which is in 121 days.
How were LifeTech Scientific Corporation’s earnings last quarter?
LifeTech Scientific Corporation released its earnings results on Mar 31, 2026. The company reported HK$0.023 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.023.
Is LifeTech Scientific Corporation overvalued?
According to Wall Street analysts LifeTech Scientific Corporation’s price is currently Overvalued.
Does LifeTech Scientific Corporation pay dividends?
LifeTech Scientific Corporation does not currently pay dividends.
What is LifeTech Scientific Corporation’s EPS estimate?
LifeTech Scientific Corporation’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does LifeTech Scientific Corporation have?
LifeTech Scientific Corporation has 4,631,712,400 shares outstanding.
What happened to LifeTech Scientific Corporation’s price movement after its last earnings report?
LifeTech Scientific Corporation reported an EPS of HK$0.023 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -4.545%.
Which hedge fund is a major shareholder of LifeTech Scientific Corporation?
Currently, no hedge funds are holding shares in HK:1302
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
LifeTech Scientific Corporation Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
46.71%
12-Months-Change
Fundamentals
Return on Equity
4.02%
Trailing 12-Months
Asset Growth
7.05%
Trailing 12-Months
Company Description
LifeTech Scientific Corporation
LifeTech Scientific Corporation, an investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. The company operates through Structural Heart Diseases Business, Peripheral Vascular Diseases Business, and Cardiac Pacing and Electrophysiology Business segments. Its products include LAmbre left atrial appendage closure systems, as well as CeraFlex, Cera, Heart, and Konara-MF VSD occluders; Ankura thoracic aortic aneurysm and abdominal aortic aneurysm stent graft systems; delivery systems, such as Fustar steerable and SteerEase introducers; Aegisy vena cava filters; Cera vascular plug systems; AcuMark sizing balloons; LawMax dilators; and SeQure snare systems, as well as pacemakers. The company is also involved in the biomedical research and development; manufacturing and trading of materials for hemp; staff training and internal personnel management business; information consulting for investors; and manufacturing and trading of medical devices, as well as technical, consulting, and technology services. It has operations in Mainland China, India, rest of Asia, Europe, South America, Africa, and internationally. LifeTech Scientific Corporation was founded in 1999 and is headquartered in Shenzhen, the People's Republic of China.
Technical Analysis
MicroPort Scientific
―
Zylox-Tonbridge Medical Technology Co., Ltd. Class H
―
MicroPort CardioFlow Medtech Corp.
―
MicroPort NeuroTech Limited
―
―
Options Prices
Currently, No data available
---